{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(6)"],"submitter":["Sanyal AJ"],"pubmed_abstract":["<h4>Background</h4>The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes.<h4>Methods</h4>Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted.<h4>Results and conclusion</h4>Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics."],"journal":["Hepatology communications"],"pagination":["e0436"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11093560"],"repository":["biostudies-literature"],"pubmed_title":["Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence."],"pmcid":["PMC11093560"],"pubmed_authors":["Kowdley KV","Pyrsopoulos NT","Bajaj JS","Sanyal AJ","Heimanson Z","Reau NS","Allen C"],"additional_accession":[]},"is_claimable":false,"name":"Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.","description":"<h4>Background</h4>The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes.<h4>Methods</h4>Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted.<h4>Results and conclusion</h4>Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-08T06:03:39.959Z","creation":"2026-06-08T03:14:21.631Z"},"accession":"S-EPMC11093560","cross_references":{"pubmed":["38727685"],"doi":["10.1097/HC9.0000000000000436"]}}